{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-25-000061","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.476790+00:00","generated_at":"2026-05-22T12:58:10.505990+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arcus Q1 net loss widens to $112M; cash $1.0B; casdatifan Phase 3 to start Q2","bullets":["Revenue fell to $28M from $145M YoY; full-year 2025 revenue guidance $75M-$90M.","Net loss of $112M vs $4M in Q1 2024; R&D expenses rose to $122M from $109M.","Cash, equivalents, marketable securities $1.0B; sufficient to fund through initial pivotal readouts.","Phase 3 PEAK-1 trial of casdatifan + cabozantinib in ccRCC expected to initiate Q2 2025.","FDA feedback on etrumadenant supports registrational path but Arcus not pursuing Phase 3 now."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-25-000061","json":"https://secwatch.observer/filing/0001724521-25-000061.json","markdown":"https://secwatch.observer/filing/0001724521-25-000061.md","text":"https://secwatch.observer/filing/0001724521-25-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000061/0001724521-25-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000061/rcus-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T12:58:10.505990+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}